GHK-Cu is a copper-binding tripeptide studied for tissue regeneration, collagen synthesis, anti-aging, and anti-inflammatory effects. Physician-reviewed. Prescription required.
GHK-Cu is a naturally occurring copper-binding tripeptide derived from the peptide GHK. It forms when GHK binds Copper. The complex acts as a signaling and copper-transport molecule that influences tissue repair, inflammation, and gene expression.
In clinical settings, GHK-Cu has been studied for its role in activating fibroblasts, modulating gene expression, and promoting antioxidant pathways. It may support collagen synthesis, tissue repair, and skin regeneration through multiple mechanisms. Individual outcomes may differ. This protocol is not intended to diagnose, treat, cure, or prevent any disease.
| Mechanism | Biological Effect |
|---|---|
| Copper chelation and delivery | Activates copper-dependent enzymes |
| Gene expression modulation | Promotes regenerative pathways |
| Fibroblast activation | Increases collagen and elastin |
| Anti-inflammatory signaling | Suppresses NF-κB cytokine pathways |
| Antioxidant effects | Reduces oxidative stress |
| Angiogenesis and remodeling | Accelerates tissue repair |
Your physician will determine eligibility based on your complete health intake. The following profiles are commonly associated with GHK-Cu protocol candidates in clinical practice:
Skin Regeneration
Individuals seeking physician-supervised skin rejuvenation and collagen support protocols.
Tissue Repair
Individuals with connective tissue concerns where GHK-Cu's fibroblast activation may be clinically relevant.
Anti-Aging Protocol
Individuals pursuing physician-reviewed longevity protocols targeting oxidative stress and cellular aging.
Combination Stack
Patients combining GHK-Cu with BPC-157 or Epitalon in a physician-reviewed multi-peptide protocol.
Determine your candidacy
A physician will review your intake and make eligibility determination within 24–48 hours.
All outcome language below reflects what has been observed in clinical and preclinical settings. Individual outcomes may differ significantly. These are not guarantees.
Dosing is determined individually by your assigned physician. The following represents typical ranges discussed in clinical literature. Do not self-administer or adjust dosing without physician guidance.
Typical Range
1–10 mg/day (form-dependent)
Administration
Subcutaneous, topical, or IV (physician-determined)
Duration
4–16 weeks (physician-determined)
Frequency
Daily to 3x weekly (physician-determined)
These ranges are indicative only. Your physician will prescribe the specific dose and schedule appropriate for your clinical profile.
Physician consultation — Virtual intake review and protocol consultation with your assigned NP/MD
Valid prescription — Issued by your attending physician upon protocol approval
Pharmacy-dispensed compound — Dispensed by our licensed 503A compounding pharmacy partner
Follow-up check-in — Physician review at protocol midpoint; reorder pathway established
Your physician will review your complete health history before determining eligibility. The following are commonly reviewed clinical considerations.